

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alan F. Schatzberg

Application No.: Not yet assigned

Filed: Herewith

For: METHODS FOR TREATING
MILD COGNITIVE IMPAIRMENT
USING A GLUCOCORTICOID-
SPECIFIC RECEPTOR ANTAGONIST

Examiner: Not yet assigned

Art Unit: Not yet assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. These references are of record in parent Application No. 09/717,703, filed with the Information Disclosure Statement of August 24, 2001. Thus, copies of the references are not enclosed. Should the Office require additional copies of these references, applicants will gladly supply them.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Ken A. Weber', written in a cursive style.

Kenneth A. Weber
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KAW:dk

FORM PTO-1449 (Modified)			Attorney Docket No.: 019904-000110US		Application No.: 09/717,703	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Alan F. Schatzberg Joseph K. Belanoff			
			Filing Date: November 20, 2000		Group: 1615	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
1	WO 97/37664	10/16/97	PCT			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
2	Aisen, Paul S., "Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies"; <i>Gerontology</i> , 43:143-149 (1997)					
3	Aisen et al., "A Pilot Study of Prednisone in Alzheimer's Disease"; <i>Dementia</i> , 7:201-206 (1996)					
4	Aisen et al., "Glucocorticoids in Alzheimer's Disease"; <i>Drugs & Aging</i> , 1:1-6 (Jan. 1998)					
5	Aisen, Paul S., "Inflammation and Alzheimer Disease"; <i>Molecular and Chemical Neuropathology</i> , 28:83-88 (1996)					
6	Behl et al., "Protection Against Oxidative Stress-induced Neuronal Cell Death—A Novel Role for RU486"; <i>European Journal of Neuroscience</i> , 9:912-920 (1997)					
7	Bertagna et al., "The New Steroid Analog RU 486 Inhibits Glucocorticoid Action in Man"; <i>J Clin Endocrinol Metab</i> , 59:25-28 (1984)					
8	Cadepond et al., "RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses"; <i>Annu. Rev. Med.</i> , 48:129-56 (1997)					
9	DeLeon et al., "Cortisol Reduces Hippocampal Glucose Metabolism in Normal Elderly, but Not in Alzheimer's Disease"; <i>J Clin Endocrinol Metab</i> , 82:3251-3259 (1997)					
10	Dodt et al., "Different Regulation of Adrenocorticotropin and Cortisol Secretion in Young, Mentally Healthy Elderly and Patients with Senile Dementia of Alzheimer's Type"; <i>J Clin Endocrinol Metab</i> , 72:272-276 (1991)					
11	Gerson et al., "Cushing Disease Presenting as Atypical Psychosis Followed by Sudden Death"; <i>Canadian J. Psychiatry</i> , 30:223 (April 1985)					
12	Greenwald et al., "Cortisol and Alzheimer's Disease, II: Dexamethasone Suppression, Dementia Severity, and Affective Symptoms"; <i>Am J. Psychiatry</i> , 143:442-446 (April 1986)					
13	Keenan et al., "The effect on memory of chronic prednisone treatment in patients with systemic disease"; <i>Neurology</i> , 47:1396-1402 (Dec. 1996)					
14	Lupien et al., "Basal Cortisol Levels and Cognitive Deficits in Human Aging"; <i>The Journal of Neuroscience</i> , 14(5):2893-2903 (May 1994)					
15	Lupien et al., "Cortisol levels during human aging predict hippocampal atrophy and memory deficits"; <i>Nature Neuroscience</i> , 1:69 (May 1998)					
16	Lupien et al., "Stress-Induced Declarative Memory Impairment in Healthy Elderly Subjects: Relationship to Cortisol Reactivity"; <i>J Clin Endocrinol Metab</i> , 82:2070-2075 (1997)					
17	Maeda et al., "Elevated Urinary Free Cortisol in Patients With Dementia"; <i>Neurobiology of Aging</i> , 12:161-163 (1991)					
18	Naimark et al., "Psychotic Symptoms in Parkinson's Disease Patients with Dementia"; <i>JAGS</i> , 44:296-299 (1996)					
19	Newcomer et al., "Decreased Memory Performance in Healthy Humans Induced by Stress-Level Cortisol Treatment"; <i>Arch Gen Psychiatry</i> , 56:527-533 (June 1999)					
20	Peterson et al., "Mild Cognitive Impairment"; <i>Arch Neurol.</i> , 56:303-308 (Mar. 1999)					
21	Peterson et al., "Mild Cognitive Impairment"; <i>NEUR</i> , 56:303-308 (1999)					
22	Porter et al., "Stress hormones and brain aging: adding injury to insult?"; <i>Nature Neuroscience</i> , 1:3,4 (May 1998)					
23	Saad et al., "Occult Cushing's Disease Presenting with Acute Psychosis"; <i>The American Journal of Medicine</i> , 76:759766 (April 1984)					

FORM PTO-1449 (Modified)		Attorney Docket No.: 019904-000110US	Application No.: 09/717,703
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Alan F. Schatzberg J o s e p h K. Belanoff	
		Filing Date: November 20, 2000	Group: 1615
_____ 24	Sapolsky, Robert M. "The Physiological Relevance of Glucocorticoid Endangerment of the Hippocampus" from <u>Brain Corticosteroid Receptors: Studies on the Mechanism, Function, and Neurotoxicity of Corticosteroid Action</u> , Edited by E. Ronald de Kloet, Efrain C. Azmitia, and Philip W. Landfield, ; <i>Annals of the New York Academy of Sciences</i> , Vol 746 pp. 194-307 (1994)		
_____ 25	Talmi et al., "Chronic RU486 Treatment Reduces Age-Related Alterations of Mouse Hippocampal Function"; <i>Neurobiology of Aging</i> , 17:9-14 (1996)		
_____ 26	Weiner et al., "Cortisol Secretion and Alzheimer's Disease Progression"; <i>Biol. Psychiatry</i> , 42:1030-1038 (1997)		
_____ 27	Adisalerts on Stn., No. 807126093 Tuor Et al., "Protection against hypoxic-ischemic damage with corticosterone and dexamethasone: inhibition of effect by a glucocorticoid antagonist, RU38486, abstract Brain Research vol 743, pp. 258-262 (Dec. 16, 1996)		

EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.